Meningitis Clinical Trial
Official title:
Cerebrospinal Fluid Pharmacokinetics of Daptomycin
This is a prospective pharmacokinetic study in patients having external ventricular drains with suspected external ventricular drain related bacterial meningitis. A single dose of daptomycin will be administered for the purposes of the study and PK samples will be obtained around this dosing.
information related to the subject's demographics, past medical history and current medical
history will be collected from the medical record. This will be collected by the research
coordinator.
The following samples will be obtained by the research coordinator or bedside RN and sent to
UPMC laboratory for evaluation.
1 teaspoon of blood for creatinine phosphokinase level will be obtained
pregnancy testing will occur if necessary - 1 teaspoon of blood Screening procedures about
30 minutes of the patient's time includes, medical record review will occur and information
related to the patients past medical history, demographics, and present condition, results
of present testing will be collected, pregnancy test- 1 teaspoon of blood, creatinine
phosphokinase - 1 teaspoon of blood. Additionally another CPK level will be obtained 36
hours post daptomycin infusion. This blood sample is a routine part of your clinical care.
The bedside RN or research coordinator will collect the blood samples and send to the lab at
UPMC for evaluation and the medical chart review will be completed by research coordinator.
if the patient meets entry criteria the following will occur at the patient's bedside in
their room. If there is a clinical indication that requires the catheter to be removed, the
removal will not be delayed for the purposes of the research study:
Patient will receive one dose of daptomycin via IV given by the bedside RN over 30 minutes
(the dosing will be based on the patient's weight- 10 milligrams per kilogram). PK sampling
will be obtained around this dosing. 10 PK samples around dosing of Daptomycin will occur-
this will be approximately 11 teaspoons (1 teaspoon per sample) and will be obtained
immediately before the Daptomycin dosing, then 1, 2, 4, 8, 10, 16, 24 and 36 hours after the
end of infusion. The research coordinator will come to the bedside and the bedside RN will
obtain these samples and will be obtained via the patient's existing IV catheter or central
line.
4 samples of cerebrospinal fluid approximately 1 teaspoon per sample will be collected on
the day daptomycin is given. These samples will be obtained by the bedside RN and taken from
the already existing spinal fluid draining catheter.
10 subjects will have these samples obtained 1, 8, 16, 24 after the end of the daptomycin
infusion and 10 subjects will have them collected at 2,4, 10 and 36 hours after the end of
the daptomycin infusion.
2 days after collection of PK samples the patient will be seen at their bedside to check how
well the patient is doing. This will take 5-10 minutes of the patient's time. If the patient
is d/c home a research coordinator will call the patient to check on their status again this
will take about 5-10 minutes
;
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03445416 -
Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
|
N/A | |
Completed |
NCT02526394 -
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
|
Phase 4 | |
Completed |
NCT01442675 -
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
|
Phase 2 | |
Completed |
NCT00539032 -
Immunology and Safety of Menactra® in Children in Saudi Arabia
|
Phase 3 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Recruiting |
NCT05496673 -
Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda
|
N/A | |
Completed |
NCT02003495 -
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
|
Phase 3 | |
Recruiting |
NCT00901602 -
Lebanese Interhospital Pneumococcal Surveillance Program
|
||
Completed |
NCT00850603 -
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
|
Phase 4 | |
Completed |
NCT02591290 -
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
|
Phase 4 | |
Completed |
NCT03112031 -
Treatment With Tamoxifen in Cryptococcal Meningitis
|
Phase 2 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Completed |
NCT03378258 -
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
|
||
Recruiting |
NCT05637645 -
Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section
|
N/A | |
Completed |
NCT02841254 -
Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies
|
N/A | |
Completed |
NCT02003313 -
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
|
Phase 3 | |
Recruiting |
NCT01619462 -
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
|
Phase 3 | |
Completed |
NCT01239043 -
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
|
Phase 2 | |
Completed |
NCT00495690 -
Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease
|
Phase 3 |